Telix Pharmaceuticals and AMNI Partner for Prostate Cancer Imaging

MELBOURNE (Australia) and LIÈGE (Belgium) – 24th October 2017. Telix announces development and commercialisation partnership with Advanced Nuclear Medicine Ingredients SA (AMNI)

Telix Pharmaceuticals is pleased to announce that it has entered into a development and commercialisation partnership with Advanced Nuclear Medicine Ingredients SA (ANMI).

To read the full ASX release please click here.